A5030038975- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Fibroblast Growth Factor Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Chronic Myeloid Leukemia Treatments
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Erythrocyte Function and Pathophysiology
- Metabolism, Diabetes, and Cancer
- Blood disorders and treatments
- Erythropoietin and Anemia Treatment
- Wnt/β-catenin signaling in development and cancer
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune cells in cancer
- Adipose Tissue and Metabolism
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Platelet Disorders and Treatments
- Neutropenia and Cancer Infections
- Histone Deacetylase Inhibitors Research
- Peptidase Inhibition and Analysis
- Glycosylation and Glycoproteins Research
Bristol-Myers Squibb (United States)
2020
Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 SMAD3 signaling, showed promising results phase 2 study.In double-blind, placebo-controlled, 3 trial, we randomly assigned patients very-low-risk, low-risk, or intermediate-risk (defined according...
FGF21 is a stress-induced hormone with potent anti-obesity, insulin-sensitizing, and hepatoprotective properties. Although proteolytic cleavage of recombinant human in preclinical species has been observed previously, the regulation endogenously produced not well understood. Here we identify fibroblast activation protein (FAP) as enzyme that cleaves inactivates FGF21. A selective chemical inhibitor, immunodepletion, or genetic deletion Fap stabilized serum. In addition, administration FAP...
Dissipating excess calories as heat through therapeutic stimulation of brown adipose tissues (BAT) has been proposed a potential treatment for obesity-linked disorders. Here, we describe the generation humanized effector-less bispecific antibody that activates fibroblast growth factor receptor (FGFR) 1/βKlotho complex, common FGF21 and FGF19. Using this molecule, show antibody-mediated activation FGFR1/βKlotho complex in mice induces sustained energy expenditure BAT, browning white tissue,...
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis. Venetoclax has promising preclinical clinical activity in ALL. Here, we report safety preliminary efficacy of venetoclax combined with chemotherapy pediatric adolescent/young adult relapsed/refractory This phase 1, open-label, two-part, multicenter study evaluated (<25 years age) The registered...
Fibroblast Activation Protein (FAP) is a membrane-bound serine protease whose expression often elevated in activated fibroblasts associated with tissue remodeling various common diseases such as cancer, arthritis and fibrosis. Like the closely related dipeptidyl peptidase DPPIV, extracellular domain of FAP can be released into circulation functional enzyme, limited studies suggest that circulating level correlates degree Here we describe novel homogeneous fluorescence intensity assay for...
Fibroblast growth factors receptors (FGFRs) are thought to initiate intracellular signaling cascades upon ligand-induced dimerization of the extracellular domain. Although existence unliganded FGFR1 dimers on surface living cells has been proposed, this notion remains rather controversial. Here, we employed time-resolved Förster resonance energy transfer combined with SNAP- and ACP-tag labeling in COS7 monitor full-length at cell-surface or without coreceptor βKlotho. Using approach observed...
Bispecific antibodies have shown promise in the clinic as medicines with novel mechanisms of action. Lack efficient production bispecific IgGs, however, has limited their rapid advancement. Here, we describe a single-reactor process using mammalian cell co-culture to efficiently produce IgG 4 distinct polypeptide chains without need for parallel processing each half-antibody or additional framework mutations. This method resembles conventional process, and quality yield monoclonal are equal...
Bispecific antibodies offer a clinically validated platform for drug discovery. In generating functionally active bispecific antibodies, it is necessary to identify unique parental antibody pair merge into single molecule. However, technologies that allow high-throughput production of immunoglobulin Gs (BsIgGs) screening purposes are limited. Here, we describe novel format termed tethered-variable CLBsIgG (tcBsIgG) allows robust intact BsIgG in cell line, concurrently ensuring cognate light...